Download FREE

Crystal Clear Vigilance: Detecting Crystallization in ASDs

While promising for improving drug bioavailability, Amorphous Solid Dispersions (ASDs) formulation creates challenges, in particular the risk of crystallization and stability issues. Therefore, ASDs require knowledgeable testing to ensure consistent product quality and efficacy throughout its lifetime.

Get the free white paper:

FDA insights

Enhance your understanding of critical factors influencing regulatory outcomes.

Challenges in ASD testing

Learn how the right expertise and equipment are paramount for risk identification.

Risk mitigation

Discover strategies to mitigate crystallization-related regulatory risks and expedite drug approval processes.